Nostrin-flox Mouse
一般名
Nostrin-flox
製品ID
S-CKO-10618
背景情報
C57BL/6JCya
系統ID
CKOCMP-329416-Nostrin-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Nostrin-flox Mouse(カタログ番号S-CKO-10618)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Nostrin-flox
系統ID
CKOCMP-329416-Nostrin-B6J-VA
遺伝子名
製品ID
S-CKO-10618
遺伝子別名
Daip2, mDaIP2
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 2
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000041865
NCBIトランスクリプトID
NM_181547
ターゲット領域
Exon 4~5
有効領域の大きさ
~1.9 kb
遺伝子研究の概要
NOSTRIN, short for nitric oxide synthase traffic inducer, is a pleiotropic regulator of endothelial cell function. It interacts with endothelial nitric oxide synthase (eNOS), modulating its subcellular distribution and NO release [7]. It also participates in multiple pathways such as those related to cell proliferation, inflammation, and angiogenesis, thus being of great biological importance. Genetic models, especially knockout models, can be valuable for studying its functions.
In murine trophoblast cells, NOSTRIN levels increase during gestation. Precocious over-expression of NOSTRIN leads to increased trophoblast giant cell (TGC) formation and invasion, as it affects the G/F actin ratio and forms complexes with proteins like N-WASP, Dynamin, and Cdk1 [1]. In cirrhosis and acute-on-chronic liver failure (ACLF) models, hepatic Nostrin expression is elevated, and its knockdown in human umbilical vein endothelial cells (HUVECs) improves eNOS activity and reduces inflammation [2]. In a benign prostatic hyperplasia (BPH) mouse model, NOSTRIN expression is inhibited. Over-expressing NOSTRIN in prostate epithelial cells inhibits proliferation, oxidative stress, and inflammation, possibly through NF-κB signaling [3]. In colon cancer cell lines, NOSTRIN over-expression reduces cell invasion, colony formation, and stemness, while its knockdown enhances metastatic potential [4]. In acute kidney injury (AKI) patients, serum Nostrin levels are higher and are associated with in-hospital death, need for kidney replacement therapy, and lack of kidney function recovery [5]. In cirrhotic patients, Nostrin expression is increased, reducing eNOS activity and local NO generation, and blood Nostrin concentration may be a biomarker for disease severity [6]. In end-stage chronic kidney disease (CKD) patients, serum Nostrin levels are further increased compared to AKI patients, indicating impaired turnover [8]. In zebrafish and mice, NOSTRIN is necessary for proper vascular development, as it impacts endothelial tip cell migration and filopodia formation, and is involved in FGF-2-dependent Rac1 activation [9].
In conclusion, NOSTRIN plays diverse and crucial roles in multiple biological processes and disease conditions. Through model-based research, especially in KO/CKO mouse models or other loss-of-function experiments, its functions in processes like trophoblast differentiation, liver disease development, BPH, colon cancer progression, kidney injury and disease, and vascular development have been revealed. These findings contribute to understanding the underlying mechanisms of these diseases and may provide potential therapeutic targets.
References:
1. Chakraborty, Shreeta, Ain, Rupasri. 2018. NOSTRIN: A novel modulator of trophoblast giant cell differentiation. In Stem cell research, 31, 135-146. doi:10.1016/j.scr.2018.07.023. https://pubmed.ncbi.nlm.nih.gov/30086473/
2. Vairappan, Balasubramaniyan, Wright, Gavin, M, Sundhar, Ravikumar, T S. 2023. Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF. In European journal of pharmacology, 958, 176010. doi:10.1016/j.ejphar.2023.176010. https://pubmed.ncbi.nlm.nih.gov/37634841/
3. Li, Shoubin, Yu, Chunhong, Xiao, Helong, Sun, Zhanxin, Liu, Junjiang. 2024. NOSTRIN is involved in benign prostatic hyperplasia via inhibition of proliferation, oxidative stress, and inflammation in prostate epithelial cells. In Translational andrology and urology, 13, 2055-2069. doi:10.21037/tau-24-209. https://pubmed.ncbi.nlm.nih.gov/39434759/
4. Paul, Madhurima, Gope, Tamal Kanti, Das, Priyanka, Ain, Rupasri. 2022. Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression. In BMC cancer, 22, 594. doi:10.1186/s12885-022-09670-6. https://pubmed.ncbi.nlm.nih.gov/35642021/
5. Erfurt, Stefan, Lauxmann, Martin, Asmus, Katharina, Patschan, Daniel, Hoffmeister, Meike. 2024. Serum Nostrin-A risk factor of death, kidney replacement therapy and acute kidney disease in acute kidney injury. In PloS one, 19, e0299131. doi:10.1371/journal.pone.0299131. https://pubmed.ncbi.nlm.nih.gov/38603667/
6. Vairappan, Balasubramaniyan, Ts, Ravikumar, Ram, Amit Kumar, Mohan, Pazhanivel, Pottakkat, Biju. 2024. NOSTRIN is an emerging positive regulator of decompensated cirrhotic patients with portal hypertension. In Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 57, 427-435. doi:10.1016/j.dld.2024.08.050. https://pubmed.ncbi.nlm.nih.gov/39294044/
7. Zimmermann, Kirstin, Opitz, Nils, Dedio, Jurgen, Muller-Esterl, Werner, Oess, Stefanie. 2002. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase. In Proceedings of the National Academy of Sciences of the United States of America, 99, 17167-72. doi:. https://pubmed.ncbi.nlm.nih.gov/12446846/
8. Latuske, Vivien, Erfurt, Stefan, Hoffmeister, Meike. 2025. End-stage chronic kidney disease affects serum Nostrin turnover. In Kidney & blood pressure research, , 1-10. doi:10.1159/000545521. https://pubmed.ncbi.nlm.nih.gov/40228481/
9. Kovacevic, Igor, Hu, Jiong, Siehoff-Icking, Ann, Hoffmeister, Meike, Oess, Stefanie. 2012. The F-BAR protein NOSTRIN participates in FGF signal transduction and vascular development. In The EMBO journal, 31, 3309-22. doi:10.1038/emboj.2012.176. https://pubmed.ncbi.nlm.nih.gov/22751148/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
